Cepheid

The company's Life Sciences segment was up 17 percent year over year, while its Diagnostics business grew 8 percent.

The test for resistance genes from carbapenemase-producing Gram-negative bacteria can now be used on perirectal swabs and pure colonies.

The test, which received FDA clearance in late 2017, runs in as little as 18 minutes.

The company's Diagnostics business was up 14 percent, while its Life Sciences business grew 13 percent. The firm also closed its $2 billion buy of IDT last week.

In Life Sciences, CEO Thomas Joyce noted a strong performance by Beckman Coulter, while in Diagnostics, he said Cepheid grew 25 percent year over year. 

The Xpert Xpress Flu can detect both influenza A and B virus in 20 minutes from either nasopharyngeal or nasal swabs.

The company said that EPS for next year is anticipated to be between $3.50 and $3.60. On an adjusted basis, EPS is expected in the range of $4.25 to $4.35. 

The firm beat the consensus Wall Street estimates on the top and bottom lines as the diagnostics segment saw revenues grow 20 percent year over year.